$LLY - Eli Lilly's GLP-1 drug has become the best-selling drug of all time with exceptional growth, surpassing Keytruda with over $8 billion in quarterly revenue growing at 80%
$INDUSTRIALS - Eli Lilly's massive expansion plans with 10 new plants will create 20,000 construction jobs and 5,000-6,000 manufacturing jobs, benefiting industrial and construction companies
$BRAIN - Brain diseases represent 40% of global human suffering with massive unmet medical needs, presenting significant opportunities for breakthrough therapeutics
$MENTAL - Eli Lilly is starting studies for GLP-1 drugs in bipolar disorder and major depressive disorder, potentially transforming mental health treatment in 3-4 years
Bearish:
$BIOTECH - Biotech funding has collapsed from $20 billion annually to $5 billion, with half of publicly traded biotech companies trading at or below cash value
$FOOD - The CEO of the leading obesity drug company criticizes processed food companies and the US food system, citing highly processed foods and chemicals as major health problems
$MEDIA - Pharmaceutical advertising may face reduction as even pharma executives support limiting drug ads that annoy consumers and comprise significant media revenue
$CHINA - Chinese pharma companies are heavily subsidized by the state, using a swarm model to copy and execute faster on derivative ideas through patent hacking